<DOC>
	<DOCNO>NCT00706433</DOCNO>
	<brief_summary>The purpose study determine compare safety efficacy multiple broad area photodynamic therapy treatment aminolevulinic acid ( ALA-PDT ) vehicle ( VEH-PDT ) subject moderate severe facial acne vulgaris .</brief_summary>
	<brief_title>Light Dose Ranging Study Photodynamic Therapy ( PDT ) With Levulan + Blue Light Versus Vehicle + Blue Light Severe Facial Acne</brief_title>
	<detailed_description>This Phase II multicenter , randomize , evaluator-blinded , vehicle-controlled , parallel group light dose range study photodynamic therapy subject moderate severe facial acne vulgaris . Subjects randomize one follow four treatment group ( 1:1:1:1 ) receive topical Levulan® Kerastick® contain 20 % aminolevulinic acid HCL ( ALA , active study drug ) Kerastick® contain vehicle ingredient ( VEH ) . - Group 1 ALA apply entire facial area 45 minute ± 15 minute prior BLUE light treatment 1000 second ( 16 minute 40 second ) - Group 2 ALA apply entire facial area 45 minute ± 15 minute prior BLUE light treatment 500 second ( 8 minute 20 second ) - Group 3 VEH apply entire facial area 45 minute ± 15 minute prior BLUE light treatment 1000 second ( 16 minute 40 second ) - Group 4 VEH apply entire facial area 45 minute ± 15 minute prior BLUE light treatment 500 second ( 8 minute 20 second ) Each subject may receive four treatment three week ( ± 2 day ) interval . The power density ( dose rate ) total fluence ( light dose ) use treatment intend remain constant throughout subject 's participation . If subject meet exceed criterion restrict retreatment ( CRR ) prior retreatment ( Section 5.6 ) , he/she receive additional PDT treatment visit ask return next schedule PDT visit 3 week later , applicable . Post-treatment follow-up visit schedule occur 3 6 week subject 's final PDT . Grading subject 's facial acne conduct blind evaluator remain blind respect subject 's treatment assignment . Tolerability treatment assess evaluation local skin response ( erythema , edema , etc . ) conduct unblinded evaluator . Safety evaluate adverse event local skin response report study .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Aminolevulinic Acid</mesh_term>
	<criteria>Subject male nonpregnant female 12 year age old . Females must postmenopausal , surgically sterile use medically acceptable form birth control , negative urine pregnancy test Baseline visit . Subject provide write verbal informed consent . A subject 18 year age must accompany parent legal guardian time assent/consent signing . The parent legal guardian must also provide informed consent subject . Subject moderate severe facial acne vulgaris ( include nose ) , least 20 inflammatory lesion ( papule , pustule , nodule ) . Subject moderate severe acne define Investigator Global Assessment 3 4 [ 0 ( clear ) 4 ( severe ) scale ] . Subject history recurrent herpes simplex labialis infection treatment area AND outbreak within last 12 month must place antiviral prophylaxis specify protocol . Subject willing comply study instruction return clinic require visit . Subject must use type brand makeup , facial product hair product ( e.g . shampoo , gel , hair spray , mousse , etc . ) least 1 month prior Baseline Visit ( General Skin &amp; Hair Care ) . Upon enrollment , subject must ) use exclusively Investigator approve facial cleanser b ) agree continue General Skin &amp; Hair Care entire study . Subject pregnant , lactating , plan become pregnant study . Subject history cutaneous photosensitization , porphyria , hypersensitivity porphyrin photodermatosis . Subject skin pathology condition could interfere evaluation test product require use interfere topical systemic therapy . Subject great 4 facial nodule ( nodule = lesion great equal 0.5 cm diameter ) Subject uncorrected coagulation defect concurrently use anticoagulant ( except aspirin ) . Subject condition , investigator 's opinion , would make unsafe subject participate research study . Subject currently enrol investigational drug device study . Subject receive investigational drug treat investigational device within 30 day prior initiation treatment ( baseline ) . Subject facial hair could interfere study assessment opinion investigator . Subject unable communicate cooperate investigator due language problem , poor mental development , impaired cerebral function . Subject may unreliable study include subject engage excessive alcohol intake drug abuse , subject unable return schedule followup visit . Subject know sensitivity one vehicle component ( ethyl alcohol , isopropyl alcohol , laureth 4 , polyethylene glycol ) . Subject use photosensitizing drug , e.g . declomycin , tetracycline , sulfa antibiotic , phenothiazine , etc . within timeframe photosensitization drug may still present . Subject use OTC acne medicate cleanser soap within 2 week initiation treatment . Subject need plan expose artificial tanning device excessive sunlight trial . Subject use follow topical antiacne preparation face : . ) Topical antiacne treatment include benzoyl peroxide , antibiotic , azelaic acid , corticosteroid salicylic acid within 2 week initiation treatment b . ) Retinoids , include tazarotene , adapalene , tretinoin within 4 week initiation treatment . c. ) Light treatment , microdermabrasion chemical peel within 8 week initiation treatment . Subject use follow systemic antiacne medication : . ) Corticosteroids ( include intramuscular intralesional injection ) within 4 week initiation treatment . Inhaled corticosteroid allow use stable ( stable use define dose frequency unchanged least 2 week prior initiation treatment ) . b . ) Antibiotics within 4 week initiation treatment . c. ) Nicotinamide contain product within 4 week initiation treatment . d. ) Spironolactone within 8 week initiation treatment . d. ) Retinoid therapy within 6 month initiation treatment .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Photodynamic Therapy</keyword>
</DOC>